Welcome to our dedicated page for Walgreen Boots SEC filings (Ticker: WBA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Walgreens Boots Alliance, Inc. filings document the company's transition out of public-company reporting after its acquisition by Sycamore Partners. The record includes Form 25 delisting materials for WBA common stock and listed notes on Nasdaq and Form 15 certification covering termination of registration or suspension of Exchange Act reporting duties.
WBA's 8-K filings also disclose material events tied to the transaction period, including shareholder voting matters, temporary suspension of trading under employee benefit plans, material agreements, capital-structure matters and operating results. The filings identify covered securities such as common stock and multiple Walgreens Boots Alliance and Walgreen Co. senior notes.
Nancy M. Schlichting, a director of Walgreens Boots Alliance, reported receiving an annual non-employee director share grant. The Form 4 shows she was issued 16,820 shares of WBA common stock on 08/13/2025 as director compensation under the company's 2021 Omnibus Incentive Plan, in arrears for services rendered the prior year. The grant price is recorded as $0, and the filing discloses that she now beneficially owns 37,961 shares. The form was signed on 08/15/2025 by an attorney-in-fact.
Walgreens Boots Alliance (WBA) – Supplemental DEFA14A for proposed Sycamore Partners take-private
The filing provides additional proxy disclosures intended to moot shareholder litigation and demand letters challenging the adequacy of the June 6, 2025 definitive proxy. The company is scheduled to hold a special meeting on July 11, 2025 to vote on the March 6, 2025 merger agreement under which Blazing Star Parent (an affiliate of Sycamore Partners) will acquire WBA.
Litigation status: Two suits (Illinois “Drulias” and New York “Johnson”) seek to enjoin the vote, alleging omissions in the proxy regarding financial projections, advisor analyses and conflicts. Eleven demand letters raise similar points. WBA considers all claims meritless but is voluntarily supplementing disclosures to avoid delays and costs.
Key new disclosures (page references to original proxy):
- Expanded background of negotiations, including Sycamore confidentiality terms, board deliberations on dividend sustainability, alternative-party outreach and Kirkland & Ellis relationships (pp. 37, 42, 57).
- Detailed quantitative inputs in Centerview’s valuation work: updated public-company multiples (mean EV/NTM EBITDA 5.9×), precedent transaction multiples (median 6.9×) and DCF assumptions (WACC 9.25-10.75%, terminal EBITDA multiple 5-7×).
- Per-share equity value ranges now explicitly stated:
- Public comps: $4.60–$12.70
- Precedent deals: $6.90–$15.20
- DCF: $10.80–$19.10
- Premiums-paid: $10.60–$12.80
- Morgan Stanley 2025E P/E comps: $7.95–$12.25
- Comprehensive forward-looking financial projections (February, VMD, October, December iterations) now presented, showing FY-2025 revenue about $154 bn and Adjusted EBITDA of $3.7 bn (2.4% margin) with modest free-cash-flow generation.
Implications for shareholders: 1) Additional transparency lowers injunction risk and improves the probability of a timely vote. 2) Valuation data allow investors to benchmark the offer price versus independent ranges; while fair relative to trading and precedent metrics, the board’s DCF indicates potential upside beyond the bid. 3) The filing highlights sizeable liabilities (opioid settlements, dark-rent, pension) and limited FCF, factors that may have compressed standalone valuation.
Walgreens Boots Alliance (NASDAQ:WBA) filed Definitive Additional Proxy Materials (DEFA14A) tied to its proposed merger with Sycamore Partners’ vehicle Blazing Star.
The filing confirms that the special shareholder meeting will be held on July 11, 2025, when investors will vote on the transaction detailed in the March 6, 2025 merger agreement. CEO Tim Wentworth’s transcript highlights Q3 FY25 progress: cost-savings in U.S. retail pharmacy, improving VillageMD and Shields performance, strong international results and higher cash flow, offset by continuing U.S. retail headwinds.
The Board unanimously recommends a FOR vote. Forward-looking language reiterates multiple risks including financing, regulatory approvals and potential termination fees. No financial terms of the merger or voting tallies are disclosed in this update.